APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 149 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,294 | -9.4% | 60,304 | +116.9% | 0.11% | -1.8% |
| Q2 2023 | $2,532 | -10.1% | 27,799 | -34.9% | 0.11% | -17.3% |
| Q1 2023 | $2,816 | +63.9% | 42,699 | +28.5% | 0.13% | +40.0% |
| Q4 2022 | $1,718 | -99.9% | 33,231 | 0.0% | 0.10% | -30.7% |
| Q3 2022 | $2,270,000 | +60.0% | 33,231 | +5.9% | 0.14% | +28.0% |
| Q2 2022 | $1,419,000 | +37.8% | 31,384 | +54.9% | 0.11% | +59.7% |
| Q1 2022 | $1,030,000 | +196.0% | 20,263 | +175.1% | 0.07% | +55.8% |
| Q4 2021 | $348,000 | -9.6% | 7,367 | -18.0% | 0.04% | -65.0% |
| Q1 2021 | $385,000 | -79.2% | 8,979 | -72.3% | 0.12% | -76.7% |
| Q4 2020 | $1,853,000 | +72.7% | 32,403 | -8.9% | 0.53% | +54.8% |
| Q3 2020 | $1,073,000 | -31.7% | 35,575 | -26.1% | 0.34% | -36.1% |
| Q2 2020 | $1,572,000 | +17.7% | 48,135 | -3.5% | 0.53% | -5.2% |
| Q1 2020 | $1,336,000 | – | 49,885 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |